As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set a goal of targeting small interfering RNA to any tissue by 2030.

Glioblastoma multiforme (GBM) is the most common type of primary brain tumor in adults and has a poor prognosis. Small interfering RNA (siRNA) can disrupt different mechanisms involved in the genesis ...

Innovent Biologics is pivoting to R&D and oncology growth in China, but high valuation and risks temper upside. Read why ...

DelveInsight's analysis shows that the UK reported the highest number of DED cases in individuals aged 50 and older, with ...

一篇题为《Direct Cytosolic Delivery of siRNA Conjugates: A Paradigm in Antiangiogenic Therapy for Choroidal Neovascularization》的文章发表于《ACS Nano》2025年第19卷。 该文章 ...

Skeletal Muscle, Piceatannol, Energy Metabolism, SIRT1, Mitochondria Share and Cite: Tsuda, H. , Uchida, T. , Okuno, S. , ...

The defects in molecular and cellular processes that constitute the triggers of specific pathologies are referred to as mechanisms of disease. Research in this area is vital for designing ...

一场医学革命正在到来。 过去，小干扰RNA（siRNA）疗法停留在罕见病领域，导致市场空间受限。然而，诺华长效降血脂药Inclisiran的获批打破了这一 ...

Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' ...

Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...

肌腱粘连是肌腱损伤后的常见并发症，TGF-β1在愈合过程中具有双重作用。南通大学研究人员开发了一种超声响应性水凝胶（URH）系统，搭载TGF-β1 siRNA纳米颗粒，通过医学超声（M-US）触发可控释放，实现TGF-β1表达的时空调控。该研究在大鼠屈肌腱损伤模型中证实 ...